-
visit: https://causalab.sph.harvard.edu/. This role is focused on pregnancy research: To evaluate the effects of treatments in pregnancy we emulate target trials using observational large healthcare
-
to the implementation of established causal inference approaches to support public health and clinical decision making. The focus will be on agentic AI for target trial specification and emulation. Basic Qualifications
-
target start date of September 1, 2026. Compensation is the equivalent annual salary of $70,000 per year. This is a full-time, benefits-eligible position. If visa sponsorship is needed, Harvard retains
-
target start date of September 1, 2026. Compensation is the equivalent annual salary of $70,000 per year. This is a full-time, benefits-eligible position. If visa sponsorship is needed, Harvard retains
-
solving tough problems in neural interfacing. Projects involve peripheral nerve regeneration, mechanoreceptor-specific targeting, and surgical reconstruction for prosthetic interfacing. Basic Qualifications
-
Python and experience with GPU cluster environments (e.g., SLURM) are a plus. Special Instructions Please provide a CV, a Research Statement, and two or more letters of recommendation. The target start
-
to study the roles of microglia and oligodendrocytes in neurodegeneration and cognitive function. Analyze high-dimensional data to identify molecular pathways and targets relevant to Alzheimer’s disease and
-
. Depending on available funding, one of the positions may be specifically targeted at candidates interested in the scaling regimes of deep networks. Basic Qualifications A PhD is required. We seek candidates
-
in neural interfacing. Projects involve peripheral nerve regeneration, mechanoreceptor-specific targeting, and surgical reconstruction for prosthetic interfacing. Deadline for application: Apr 15, 2025
-
characterization of neofunctionalized enzymes in plant metabolism, 2) elucidation and engineering of biosynthetic pathways for high-value molecules from plants, and 3) identifying the native targets of bioactive